Community risk factors for ocular Chlamydia infection in Niger: pre-treatment results from a cluster-randomized trachoma trial

Abdou Amza, Boubacar Kadri, Baido Nassirou, Nicole E Stoller, Sun N Yu, Zhaoxia Zhou, Stephanie Chin, Sheila K West, Robin L Bailey, David C W Mabey, Jeremy D Keenan, Travis C Porco, Thomas M Lietman, Bruce D Gaynor, PRET Partnership, Abdou Amza, Boubacar Kadri, Baido Nassirou, Nicole E Stoller, Sun N Yu, Zhaoxia Zhou, Stephanie Chin, Sheila K West, Robin L Bailey, David C W Mabey, Jeremy D Keenan, Travis C Porco, Thomas M Lietman, Bruce D Gaynor, PRET Partnership

Abstract

Background: Trachoma control programs utilize mass azithromycin distributions to treat ocular Chlamydia trachomatis as part of an effort to eliminate this disease world-wide. But it remains unclear what the community-level risk factors are for infection.

Methods: This cluster-randomized, controlled trial entered 48 randomly selected communities in a 2×2 factorial design evaluating the effect of different treatment frequencies and treatment coverage levels. A pretreatment census and examination established the prevalence of risk factors for clinical trachoma and ocular chlamydia infection including years of education of household head, distance to primary water source, presence of household latrine, and facial cleanliness (ocular discharge, nasal discharge, and presence of facial flies). Univariate and multivariate associations were tested using linear regression and Bayes model averaging.

Findings: There were a total of 24,536 participants (4,484 children aged 0-5 years) in 6,235 households in the study. Before treatment in May to July 2010, the community-level prevalence of active trachoma (TF or TI utilizing the World Health Organization [WHO] grading system) was 26.0% (95% CI: 21.9% to 30.0%) and the mean community-level prevalence of chlamydia infection by Amplicor PCR was 20.7% (95% CI: 16.5% to 24.9%) in children aged 0-5 years. Univariate analysis showed that nasal discharge (0.29, 95% CI: 0.04 to 0.54; P = 0.03), presence of flies on the face (0.40, 95% CI: 0.17 to 0.64; P = 0.001), and years of formal education completed by the head of household (0.07, 95% CI: 0.07 to 0.13; P = 0.03) were independent risk factors for chlamydia infection. In multivariate analysis, facial flies (0.26, 95% CI: 0.02 to 0.49; P = 0.03) and years of formal education completed by the head of household (0.06, 95% CI: 0.008 to 0.11; P = 0.02) were associated risk factors for ocular chlamydial infection.

Interpretation: We have found that the presence of facial flies and years of education of the head of the household are risk factors for chlamydia infection when the analysis is done at the community level.

Trial registration: ClinicalTrials.gov NCT00792922.

Conflict of interest statement

The authors have declared that no competing interests exist.

Figures

Figure 1. Consort flow diagram: cluster-randomized trachoma…
Figure 1. Consort flow diagram: cluster-randomized trachoma trial in Niger.

References

    1. Report of the Eighth Meeting of the W.H.O. Alliance for the Global Elimination of Blinding Trachoma. Geneva, Switzerland: World Health Organization. 2004. WHO/PBD/GET/04.2 WHO/PBD/GET/04.2.
    1. Emerson PM, Lindsay SW, Alexander N, Bah M, Dibba SM, et al. Role of flies and provision of latrines in trachoma control: cluster-randomised controlled trial. Lancet. 2004;363:1093–1098.
    1. West S, Muñoz B, Lynch M, Kayongoya A, Chilangwa Z, et al. Impact of face-washing on trachoma in Kongwa, Tanzania. Lancet. 1995;345:155–158.
    1. Stare D, Harding-Esch E, Munoz B, Bailey R, Mabey D, et al. Design and baseline data of a randomized trial to evaluate coverage and frequency of mass treatment with azithromycin: the Partnership for Rapid Elimination of Trachoma (PRET) in Tanzania and The Gambia. Ophthalmic Epidemiology. 2011;18:20–29.
    1. Harding-Esch EM, Edwards T, Mkocha H, Munoz B, Holland MJ, et al. Trachoma prevalence and associated risk factors in the gambia and Tanzania: baseline results of a cluster randomised controlled trial. PLoS Negl Trop Dis. 2010;4:e861.
    1. Human Development Report 2010. The Real Wealth of Nations: Pathways to Human Development. New York: Palgrave Macmillan; 2010.
    1. World Health Statistics. Geneva, Switzerland: World Health Organization; 2007.
    1. Report of the Twelfth Meeting WHO Alliance for Global Elimination fo Blinding Trachoma. Geneva, Switzerland: World Health Organization; 2008.
    1. House JI, Ayele B, Porco TC, Zhou Z, Hong KC, et al. Assessment of herd protection against trachoma due to repeated mass antibiotic distributions: a cluster-randomised trial. Lancet. 2009;373:1111–1118.
    1. Melese M, Alemayehu W, Lakew T, Yi E, House J, et al. Comparison of annual and biannual mass antibiotic administration for elimination of infectious trachoma. Jama. 2008;299:778–784.
    1. Thylefors B, Dawson CR, Jones BR, West SK, Taylor HR. A simple system for the assessment of trachoma and its complications. Bulletin of the World Health Organization. 1987;65:477–483.
    1. Gaydos CA, Crotchfelt KA, Shah N, Tennant M, Quinn TC, et al. Evaluation of dry and wet transported intravaginal swabs in detection of Chlamydia trachomatis and Neisseria gonorrhoeae infections in female soldiers by PCR. Journal of Clinical Microbiology. 2002;40:758–761.
    1. Diamont J, Moncada J, Pang F, Jha H, Benes R, et al. Pooling of Chlamydial Laboratory Tests to Determine Prevalence of Trachoma. Ophthalmic Epidemiology. 2001;8:109–117.
    1. Freedman DA. A note on screening regression equations. The American Statistician. 1983;37:152–155.
    1. Hoeting JA, Madigan D, Raftery AE, Volinsky CT. Bayesian model averaging: A tutorial. Statistical Science. 1999;14:382–417.
    1. Efron B, Tibshirani RJ Hall/CRC C, editor. Boca Raton, Florida: CRC Press, LLC; 1994. An introduction to the Bootstrap;
    1. Reinhards J, Weber A, Nizetic B, Kupka K, Maxwell-Lyons F. Studies in the epidemiology and control of seasonal conjunctivitis and trachoma in southern Morocco. Bulletin of the World Health Organization. 1968;39:497–545.
    1. Taylor HR, West SK, Mmbaga BB, Katala SJ, Turner V, et al. Hygiene factors and increased risk of trachoma in central Tanzania. Archives of Ophthalmology. 1989;107:1821–1825.
    1. West SK, Emerson PM, Mkocha H, McHiwa W, Munoz B, et al. Intensive insecticide spraying for fly control after mass antibiotic treatment for trachoma in a hyperendemic setting: a randomised trial. Lancet. 2006;368:596–600.
    1. Miller K, Pakpour N, Yi E, Melese M, Alemayehu W, et al. Pesky trachoma suspect finally caught. Br J Ophthalmol. 2004;88:750–751.
    1. Emerson PM, Bailey RL, Mahdi OS, Walraven GE, Lindsay SW. Transmission ecology of the fly Musca sorbens, a putative vector of trachoma. Transactions of the Royal Society of Tropical Medicine and Hygiene. 2000;94:28–32.
    1. Dolin PJ, Faal H, Johnson GJ, Minassian D, Sowa S, et al. Reduction of trachoma in a sub-Saharan village in absence of a disease control programme. Lancet. 1997;349:1511–1512.
    1. Fouad D, Mousa A, Courtright P. Sociodemographic characteristics associated with blindness in a Nile Delta governorate of Egypt. British Journal of Ophthalmology. 2004;88:614–618.
    1. Montgomery MA, Desai MM, Elimelech M. Assessment of latrine use and quality and association with risk of trachoma in rural Tanzania. Transactions of the Royal Society of Tropical Medicine and Hygiene. 2010;104:283–289.
    1. Schemann JF, Sacko D, Malvy D, Momo G, Traore L, et al. Risk factors for trachoma in Mali. International Journal of Epidemiology. 2002;31:194–201.
    1. Wright HR, Turner A, Taylor HR. Trachoma. Lancet. 2008;371:1945–1954.
    1. Resnikoff S, Peyramaure F, Bagayogo CO, Huguet P. Health education and antibiotic therapy in trachoma control. Revue Internationale du Trachome et de Pathologie Oculaire Tropicale et Subtropicale et de Sante Publique. 1995;72:89–98, 101–110.
    1. Blake IM, Burton MJ, Bailey RL, Solomon AW, West S, et al. Estimating household and community transmission of ocular Chlamydia trachomatis. PLoS Negl Trop Dis. 2009;3:e401.
    1. Bailey R, Osmond C, Mabey DC, Whittle HC, Ward ME. Analysis of the household distribution of trachoma in a Gambian village using a Monte Carlo simulation procedure. International Journal of Epidemiology. 1989;18:944–951.
    1. Katz J, Zeger SL, Tielsch JM. Village and household clustering of xerophthalmia and trachoma. International Journal of Epidemiology. 1988;17:865–869.
    1. Schachter J, West SK, Mabey D, Dawson CR, Bobo L, et al. Azithromycin in control of trachoma. Lancet. 1999;354:630–635.
    1. Keenan JD, Lakew T, Alemayehu W, Melese M, House JI, et al. Slow resolution of clinically active trachoma following successful mass antibiotic treatments. Archives of Ophthalmology. 2011;129:512–513.
    1. Wright HR, Taylor HR. Clinical examination and laboratory tests for estimation of trachoma prevalence in a remote setting: what are they really telling us? Lancet Infect Dis. 2005;5:313–320.
    1. Abdou A, Nassirou B, Kadri B, Moussa F, Munoz BE, et al. Prevalence and risk factors for trachoma and ocular Chlamydia trachomatis infection in Niger. British Journal of Ophthalmology. 2007;91:13–17.
    1. See CW, Alemayehu W, Melese M, Zhou Z, Porco TC, et al. How reliable are tests for trachoma?–a latent class approach. Investigative Ophthalmology and Visual Science. 2011;52:6133–6137.
    1. Solomon AW, Foster A, Mabey DC. Clinical examination versus Chlamydia trachomatis assays to guide antibiotic use in trachoma control programmes. Lancet Infect Dis. 2006;6:5–6; author reply 7–8.

Source: PubMed

Szponzorok és közreműködők

Egészségi állapot

Kábítószer-beavatkozások

3
Iratkozz fel